Journal
Annals of Clinical and Translational Neurology
Publication Date
12-1-2024
Volume
11
Issue
12
First Page
3215
Last Page
3226
Document Type
Open Access Publication
DOI
10.1002/acn3.52229
Rights and Permissions
Newsome, S.D., Goldstick, L., Robertson, D.S., Bowen, J.D., Naismith, R.T., Townsend, B., Figueiredo, C., Kletzl, H., Giraudon, M., Bortolami, O., Zecevic, D., Giacobino, C., Clinch, S., Shen, Y.-A., Deol-Bhullar, G. and Bermel, R.A. (2024), Subcutaneous ocrelizumab in multiple sclerosis: Results of the Phase 1b OCARINA I study. Ann Clin Transl Neurol, 11: 3215-3226. https://doi.org/10.1002/acn3.52229 © 2024 The Author(s). Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Recommended Citation
Newsome, Scott D; Naismith, Robert T; and et al., "Subcutaneous ocrelizumab in multiple sclerosis: Results of the Phase 1b OCARINA I study." Annals of Clinical and Translational Neurology. 11, 12. 3215 - 3226. (2024).
https://digitalcommons.wustl.edu/oa_4/6973
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
